当前位置:首页 >财报库 > 报告详情

Heart Test Laboratories, Inc(HSCS, HSCSW)美股招股说明书 S-1 (2024-09-27修订版)(英文版)(88页).pdf

上传人: 1539****815 编号:896258 2024-09-27 88页 1.76MB

1、S-1/A 1 ea0215597-01.htm REGISTRATION STATEMENTAs filed with the Securities and Exchange Commission on September 27,2024.Registration No.333-272501UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,DC 20549Amendment No.2 toFORM S-1REGISTRATION STATEMENTUnderTHE SECURITIES ACT OF 1933Heart Tes

2、t Laboratories,Inc.(Exact name of registrant as specified in its charter)_Texas33451026-1344466(State or otherjurisdiction ofincorporation ororganization)(Primary StandardIndustrialClassification CodeNumber)(I.R.S.EmployerIdentification Number)550 Reserve St,Suite 360Southlake,Texas 76092682-237-778

3、1(Address,includingzipcode,andtelephonenumber,includingareacode,ofregistrantsprinciDanielle Watson550 Reserve St,Suite 360Southlake,Texas 76092682-237-7781(Name,address,including zip code,and telephone number,including areacode,of agent for service)_Copies to:Sasha AblovatskiyJonathan ShechterFoley

4、Shechter Ablovatskiy LLP641 Lexington Avenue,14th FloorNewYork,NewYork 10022Tel:(212)335-0466David E.DanovitchAngela GomesSullivan&Worcester LLP1251 Avenue of the AmericasNewYork,NewYork 10020(212)660-3000_Approximate date of commencement of proposed sale to the public:As soon as practicable after t

5、heeffective date of this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basispursuant to Rule415 under the Securities Actof1933,check the following box:If this Form is filed to register additional securities for an offering

6、pursuant to Rule462(b)underthe Securities Act,please check the following box and list the Securities Act registration statement number ofthe earlier effective registration statement for the same offering.If this Form is a post-effective amendment filed pursuant to Rule462(c)under the Securities Act,

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是全文关键点的概括: 1. **公司概况**:Heart Test Laboratories, Inc. 是一家专注于将人工智能技术应用于心电图(ECG)的医疗科技公司,旨在通过开发基于AI的ECG算法(AI-ECG)来扩展和提升ECG的临床应用。 2. **产品与服务**:公司正在开发MyoVista wavECG设备,这是一种结合了AI-ECG算法的12导联心电图设备,旨在检测心脏功能障碍。此外,公司还在开发MyoVista Insights Cloud Platform,一个基于云的平台,用于托管和集成AI-ECG算法。 3. **市场机会**:全球每年进行超过1.5亿到3000万次ECG检查,市场预计将从2023年的109.3亿美元增长到2032年的255.6亿美元。 4. **风险因素**:公司面临FDA审批、市场竞争、研发成本和全球宏观经济环境等风险。 5. **财务信息**:公司计划通过首次公开募股(IPO)发行最多1882.353万股普通股,每股面值0.001美元。 6. **未来展望**:公司预计未来将需要额外的资金来支持产品开发、市场推广和运营。
"AI-ECG技术,心脏疾病的早期发现利器?" "MyoVista wavECG,革新心电图检测新篇章?" "从“沉默杀手”到“早期预警”,心脏健康新选择!"
客服
商务合作
小程序
服务号
折叠